KR20150040289A - 인플루엔자에서의 위험도 계층화 - Google Patents

인플루엔자에서의 위험도 계층화 Download PDF

Info

Publication number
KR20150040289A
KR20150040289A KR20157003223A KR20157003223A KR20150040289A KR 20150040289 A KR20150040289 A KR 20150040289A KR 20157003223 A KR20157003223 A KR 20157003223A KR 20157003223 A KR20157003223 A KR 20157003223A KR 20150040289 A KR20150040289 A KR 20150040289A
Authority
KR
South Korea
Prior art keywords
ifi27
level
gene product
seq
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20157003223A
Other languages
English (en)
Korean (ko)
Inventor
안토니 맥클린
벤자민 탕
그랜트 피터 파르넬
마리암 쇼자에이
Original Assignee
네피안 블루 마운틴스 로컬 헬스 디스트릭트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902954A external-priority patent/AU2012902954A0/en
Application filed by 네피안 블루 마운틴스 로컬 헬스 디스트릭트 filed Critical 네피안 블루 마운틴스 로컬 헬스 디스트릭트
Publication of KR20150040289A publication Critical patent/KR20150040289A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866Interferon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR20157003223A 2012-07-10 2013-07-10 인플루엔자에서의 위험도 계층화 Withdrawn KR20150040289A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902954A AU2012902954A0 (en) 2012-07-10 Risk stratification in influenza
AU2012902954 2012-07-10
PCT/AU2013/000765 WO2014008545A1 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Publications (1)

Publication Number Publication Date
KR20150040289A true KR20150040289A (ko) 2015-04-14

Family

ID=49915252

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157003223A Withdrawn KR20150040289A (ko) 2012-07-10 2013-07-10 인플루엔자에서의 위험도 계층화

Country Status (10)

Country Link
US (2) US10036075B2 (enExample)
EP (1) EP2872891B1 (enExample)
JP (1) JP6097388B2 (enExample)
KR (1) KR20150040289A (enExample)
CN (1) CN104769430B (enExample)
AU (1) AU2013289854B2 (enExample)
BR (1) BR112015000685A2 (enExample)
CA (1) CA2877400A1 (enExample)
DK (1) DK2872891T3 (enExample)
WO (1) WO2014008545A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2886979T3 (es) 2012-02-09 2021-12-21 Memed Diagnostics Ltd Distintivos y determinantes para diagnosticar infecciones y métodos para usarlos
WO2015103664A1 (en) * 2014-01-09 2015-07-16 Nepean Blue Montains Local Health District Risk stratification in influenza
EP3180621B1 (en) 2014-08-14 2020-04-01 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3146974A1 (en) 2015-09-25 2017-03-29 Universite Claude Bernard - Lyon 1 Biomarkers for early determination of severity of influenza related disease
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
IL287757B (en) * 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
CN109804245B (zh) 2016-07-10 2022-10-25 米密德诊断学有限公司 感染的早期诊断
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US12344893B2 (en) 2018-06-05 2025-07-01 Washington University Nasal genes used to identify, characterize, and diagnose viral respiratory infections
CN115136009A (zh) * 2020-04-09 2022-09-30 B.R.A.H.M.S有限公司 用于呼吸道感染诊断的生物标志物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792626A (en) * 1996-09-18 1998-08-11 Incyte Pharmaceuticals, Inc. Human interferon-inducible protein
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US7214498B2 (en) * 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP2008504803A (ja) * 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2007034280A2 (en) * 2005-09-19 2007-03-29 Moshe Amihood Blay Composition and method for prevention of influenza
SG177956A1 (en) * 2006-08-11 2012-02-28 Baylor Res Inst Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections
WO2009148150A1 (ja) * 2008-06-06 2009-12-10 国立大学法人富山大学 インフルエンザウィルス検出用デバイス
US20120009148A1 (en) * 2008-12-29 2012-01-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
US20120077767A1 (en) * 2009-05-26 2012-03-29 Zaas Aimee K Molecular predictors of fungal infection
WO2011005793A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Cell-based bioprocessing
WO2011038363A2 (en) * 2009-09-28 2011-03-31 The Regents Of The University Of California Beta-defensin 2 genetic variation predicts h. pylori susceptibility
US20140228243A1 (en) * 2011-09-04 2014-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Prognostic methods and compositions for predicting interferon treatment eficacy in a subject

Also Published As

Publication number Publication date
CA2877400A1 (en) 2014-01-16
EP2872891A4 (en) 2016-01-20
AU2013289854A2 (en) 2015-02-26
DK2872891T3 (da) 2019-05-13
AU2013289854B2 (en) 2016-03-24
US10036075B2 (en) 2018-07-31
US20150322538A1 (en) 2015-11-12
EP2872891A1 (en) 2015-05-20
JP2015530868A (ja) 2015-10-29
JP6097388B2 (ja) 2017-03-15
WO2014008545A1 (en) 2014-01-16
EP2872891B1 (en) 2019-03-13
US20180298455A1 (en) 2018-10-18
BR112015000685A2 (pt) 2017-11-28
CN104769430B (zh) 2018-12-14
AU2013289854A1 (en) 2015-01-22
CN104769430A (zh) 2015-07-08

Similar Documents

Publication Publication Date Title
US10036075B2 (en) Risk stratification in influenza
Wei et al. Hypomethylation of the IL17RC promoter associates with age-related macular degeneration
US20190367984A1 (en) Methods for predicting response to anti-tnf therapy
JP2016526888A (ja) 敗血症バイオマーカー及びそれらの使用
Mehana et al. LncRNA MEG3 regulates the interplay between Th17 and Treg cells in Behçet's disease and systemic lupus erythematosus
US20240131050A1 (en) Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
Hatami et al. STAT5a and STAT6 gene expression levels in multiple sclerosis patients
WO2012169887A2 (en) Use of new markers in a diagnostic assay for determining severity of rsv infection
WO2021250028A1 (en) Methods for detecting and treating covid patients requiring intensive care
Panthagani et al. Conjunctival transcriptomics in ocular mucous membrane pemphigoid
Ji et al. Hsa_circ_0008301 as a potential biomarker of disease activity for primary Sjogren's syndrome: Increased expression in peripheral blood of patients with primary Sjogren's syndrome
Mišunová et al. Molecular markers of systemic autoimmune disorders: the expression of MHC-located HSP70 genes is significantly associated with autoimmunity development
Al-Tae et al. Interleukin− 37 in rheumatoid arthritis: correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq
CN116997663A (zh) 类风湿性关节炎发作的标志物和细胞前因
Karabacak et al. Is microRNA 1910-3p (miR-1910-3p) a really distinctive marker for psoriasis?
WO2015103664A1 (en) Risk stratification in influenza
Fadhil et al. Nuclear factor-kappa B gene Polymorphism and Interleukin-8 in Iraqi population with severe chronic periodontitis
Zhao et al. Systematic and integrated analysis of tRNA-derived small RNAs reveals novel potential pathogenesis targets of sarcoidosis
Reşorlu et al. Comparison of IL-17, IL-33 and MMP-3 gene expression levels between patients with psoriasis and psoriatic arthritis and healthy controls
Cui et al. Long non-coding RNA HOXA-AS3 promotes glioma progression via miR-542-5p/HOXA1 axis
Mohareb et al. Detection of STAT4 in Multiple Sclerosis patients by polymerase chain reaction and flowcytometry
Li et al. SLC43A3 Promotes Oncogenesis and Predicts Poor Prognosis in Glioma
Bingen Monocyte Macrophage Biomarkers of Multiple Sclerosis in an Underrepresented Minority Population
Aboutaleb et al. Inflammasome NLRP3 Expression in PBMCs and Plasma Interleukin-21 in Psoriasis
Munasinghe et al. A Myeloid Lineage Signifying Anti-Tumor Necrosis Factor Resistance in Crohn’s Disease.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid